title: Safety and tolerance of Navelbine in phase I-II clinical studies.
authors.affiliation: Centre de recherche Pierre Fabre, Castres, France.
authors.forename: M
authors.initials: M
authors.lastname: Besenval
authors.forename: M
authors.initials: M
authors.lastname: Delgado
authors.forename: J P
authors.initials: JP
authors.lastname: Demarez
authors.forename: A
authors.initials: A
authors.lastname: Krikorian
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D001943:Breast Neoplasms / Q000188:drug therapy; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D004341:Drug Evaluation; D004361:Drug Tolerance; D005260:Female; D005602:France; D006801:Humans; D007558:Italy; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D015337:Multicenter Studies as Topic; D009325:Nausea / Q000139:chemically induced; D009422:Nervous System Diseases / Q000139:chemically induced; D010051:Ovarian Neoplasms / Q000188:drug therapy; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine; D014839:Vomiting / Q000139:chemically induced
chemical_list: D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine